Recent developments at the Food and Drug Administration have centered on the resignation of Commissioner Marty Makary in mid-May 2026, followed by President Trump’s Truth Social announcement naming Kyle Diamantas acting commissioner. This direct endorsement from the administration has elevated Diamantas in trader assessments for a formal permanent selection, reflecting the White House’s preference for continuity within the agency’s leadership structure. Senate confirmation remains a required step under standard executive branch procedures, and the market’s December 31 resolution window leaves room for additional candidates or delays. Other listed individuals show limited recent signals of consideration, underscoring how the acting appointment and timing of the leadership transition continue to shape implied probabilities among participants.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於Kyle Diamantas 54%
No announcement by December 31 10.2%
Stephen Hahn 5%
Brett Giroir 4.0%
最新
最新
2026-12-31
Kyle Diamantas
54%
Stephen Hahn
5%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
10%
Kyle Diamantas 54%
No announcement by December 31 10.2%
Stephen Hahn 5%
Brett Giroir 4.0%
最新
最新
2026-12-31
Kyle Diamantas
$1,525 交易量
54%
Stephen Hahn
$976 交易量
5%
Brett Giroir
$1,510 交易量
4%
Grace Graham
$1,893 交易量
3%
Sara Brenner
$849 交易量
3%
No announcement by December 31
$533 交易量
10%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments at the Food and Drug Administration have centered on the resignation of Commissioner Marty Makary in mid-May 2026, followed by President Trump’s Truth Social announcement naming Kyle Diamantas acting commissioner. This direct endorsement from the administration has elevated Diamantas in trader assessments for a formal permanent selection, reflecting the White House’s preference for continuity within the agency’s leadership structure. Senate confirmation remains a required step under standard executive branch procedures, and the market’s December 31 resolution window leaves room for additional candidates or delays. Other listed individuals show limited recent signals of consideration, underscoring how the acting appointment and timing of the leadership transition continue to shape implied probabilities among participants.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
市場開放時間： May 12, 2026, 7:59 PM ET
交易量
$7,286結束日期
2026-12-31市場開放時間
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments at the Food and Drug Administration have centered on the resignation of Commissioner Marty Makary in mid-May 2026, followed by President Trump’s Truth Social announcement naming Kyle Diamantas acting commissioner. This direct endorsement from the administration has elevated Diamantas in trader assessments for a formal permanent selection, reflecting the White House’s preference for continuity within the agency’s leadership structure. Senate confirmation remains a required step under standard executive branch procedures, and the market’s December 31 resolution window leaves room for additional candidates or delays. Other listed individuals show limited recent signals of consideration, underscoring how the acting appointment and timing of the leadership transition continue to shape implied probabilities among participants.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$7,286結束日期
2026-12-31市場開放時間
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent developments at the Food and Drug Administration have centered on the resignation of Commissioner Marty Makary in mid-May 2026, followed by President Trump’s Truth Social announcement naming Kyle Diamantas acting commissioner. This direct endorsement from the administration has elevated Diamantas in trader assessments for a formal permanent selection, reflecting the White House’s preference for continuity within the agency’s leadership structure. Senate confirmation remains a required step under standard executive branch procedures, and the market’s December 31 resolution window leaves room for additional candidates or delays. Other listed individuals show limited recent signals of consideration, underscoring how the acting appointment and timing of the leadership transition continue to shape implied probabilities among participants.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions